Ensysce Biosciences, Inc. 10-Q

Item 1. Financial Statements. Ensysce Biosciences, Inc. Consolidated Balance Sheets (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 4,153,592 $ 1,123,604 Unbilled receivable 1,782,805 97,561 Prepaid expenses and other current assets 3,154,110 1,067,703 Total current assets 9,090,507 2,288,868 Other assets 294,217 419,217 Total assets $ 9,384,724 $ 2,708,085 Liabilities and stockholders’ equity (deficit) Current liabilities: Accounts payable $ 1,967,573 $ 1,936,007 Accrued expenses and other liabilities 447,035 542,260 Notes payable and accrued interest 387,176 854,697 Total current liabilities 2,801,784 3,332,964 Long-term liabilities: Liability classified warrants 3,213 26,388 Total long-term liabilities 3,213 26,388 Total liabilities $ 2,804,997 $ 3,359,352 Commitments and contingencies (Note 6) - - Stockholders’ equity (deficit) Preferred stock, $ 0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2024 (unaudited) and December 31, 2023 $ - $ - Common stock, $ 0.0001 par value, 250,000,000 shares authorized at September 30, 2024 (unaudited) and December 31, 2023; 13,870,591 and 3,146,157 shares issued at September 30, 2024 (unaudited) and December 31, 2023, respectively; 13,870,510 and 3,146,076 shares outstanding at September 30, 2024 (unaudited) and December 31, 2023, respectively 1,387 315 Additional paid-in capital 132,886,700 121,233,901 Accumulated deficit ( 125,979,877 ) ( 121,557,074 ) Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 6,908,210 ( 322,858 ) Noncontrolling interests in stockholders’ deficit ( 328,483 ) ( 328,409 ) Total stockholders’ equity (deficit) 6,579,727 ( 651,267 ) Total liabilities and stockholders’ equity (deficit) $ 9,384,724 $ 2,708,085 The accompanying notes are an integral part of these consolidated financial statements. 1 Ensysce Biosciences, Inc. Consolidated Statements of Operations (Unaudited) 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Federal grants $ 3,418,853 $ 435,380 $ 3,906,372 $ 1,715,488 Operating expenses: Research and development 1,690,674 1,914,970 3,416,807 5,354,713 General and administrative 1,083,433 1,227,724 3,643,223 3,923,277 Total operating expenses 2,774,107 3,142,694 7,060,030 9,277,990 Income (loss) from operations 644,746 ( 2,707,314 ) ( 3,153,658 ) ( 7,562,502 ) Other income (expense): Change in fair value of convertible notes - - - 146,479 Change in fair value of liability classified warrants 6,403 17,223 23,175 279,873 Interest expense, net ( 4,063 ) ( 7,649 ) ( 1,279,691 ) ( 9,146 ) Other income (expense), net 14,683 6,934 ( 12,413 ) 23,382 Total other income (expense), net 17,023 16,508 ( 1,268,929 ) 440,588 Net income (loss) $ 661,769 $ ( 2,690,806 ) $ ( 4,422,587 ) $ ( 7,121,914 ) Net loss attributable to noncontrolling interests - ( 1,235 ) ( 74 ) ( 12,236 ) Deemed dividend related to warrants down round provision - - 290 12,038 Net income (loss) attributable to common stockholders $ 661,769 $ ( 2,689,571 ) $ ( 4,422,803 ) $ ( 7,121,716 ) Net income (loss) per basic and diluted share: Net income (loss) per share attributable to common stockholders, basic and diluted $ 0.07 $ ( 0.87 ) $ ( 0.57 ) $ ( 3.32 ) Weighted average common shares outstanding, basic and diluted 9,890,390 3,085,873 7,782,540 2,145,505 The accompanying notes are an integral part of these consolidated financial statements. 2 Ensysce Biosciences, Inc. Consolidated Statements of Changes in Stockholders’ EQUITY (Deficit) (Unaudited) Number of Shares Amount Paid-In Capital Accumulated Deficit Noncontrolling interests Total Stockholders’ Equity (Deficit) Common Stock Additional Number of Shares Amount Paid-In Capital Accumulated Deficit Noncontrolling interests Total Balance on June 30, 2023 2,669,792 $ 267 $ 119,481,957 $ ( 115,363,208 ) $ ( 326,209 ) $ 3,792,807 Settlement of restricted stock units 314 - - - - - Issuance of common stock upon exercise of warrants 193,898 20 ( 20 ) - - - Stock-based compensation - - 55,674 - - 55,674 Net loss - - - ( 2,689,571 ) ( 1,235 ) ( 2,690,806 ) Balance on September 30, 2023 2,864,004 $ 287 $ 119,537,611 $ ( 118,052,779 ) $ ( 327,444 ) $ 1,157,675 Balance on June 30, 2024 8,151,172 $ 815 $ 128,448,699 $ ( 126,641,646 ) $ ( 328,483 ) $ 1,479,385 Public offering 3,553,194 355 1,669,646 - - 1,670,001 Issuance of common stock upon warrant inducement 2,166,144 217 3,385,430 - - 3,385,647 Transaction costs associated with public offering and warrant inducement - - ( 637,894 ) - - ( 637,894 ) Stock-based compensation - - 20,819 - - 20,819 Net income - - 661,769 - 661,769 Balance on September 30, 2024 13,870,510 $ 1,387 $ 132,886,700 $ ( 125,979,877 ) $ ( 328,483 ) $ 6,579,727 Balance on December 31, 2022 534,490 $ 53 $ 107,216,566 $ ( 110,931,063 ) $ ( 315,208 ) $ ( 4,029,652 ) Settlement of restricted stock units 938 - - - - - Settlement of commitment fee 44,444 4 399,996 - - 400,000 Conversion of convertible notes 408,580 41 3,056,851 - - 3,056,892 Public offerings, net 1,381,619 139 9,049,865 - - 9,050,004 Transaction costs associated with public offerings - - ( 447,879 ) - - ( 447,879 ) Issuance of common stock upon exercise of warrants 494,795 50 ( 50 ) - - - Stock-based compensation - - 250,224 - 250,224 Reverse split fractional shares ( 862 ) - - - - - Deemed dividend related to warrants down round provision - - 12,038 ( 12,038 ) - - Net loss - - - ( 7,109,678 ) ( 12,236 ) ( 7,121,914 ) Balance on September 30, 2023 2,864,004 $ 287 $ 119,537,611 $ ( 118,052,779 ) $ ( 327,444 ) $ 1,157,675 Balance on December 31, 2023 3,146,076 $ 315 $ 121,233,901 $ ( 121,557,074 ) $ ( 328,409 ) $ ( 651,267 ) Balance 3,146,076 $ 315 $ 121,233,901 $ ( 121,557,074 ) $ ( 328,409 ) $ ( 651,267 ) Settlement of restricted stock units 63 - - - - - Conversion of convertible notes 745,521 75 1,168,525 - - 1,168,600 Public offering 3,553,194 355 1,669,646 - - 1,670,001 Public offering, net 3,553,194 355 1,669,646 1,670,001 Issuance of common stock upon exercise of warrants 1,323,904 132 2,075,087 - - 2,075,219 Issuance of common stock upon warrant inducements 5,101,752 510 8,103,433 - - 8,103,943 Transaction costs associated with public offering and warrant inducements - - ( 1,444,756 ) - - ( 1,444,756 ) Stock-based compensation - - 80,574 - - 80,574 Deemed dividend related to warrants down round provision - - 290 ( 290 ) - - Net loss - - - ( 4,422,513 ) ( 74 ) ( 4,422,587 ) Net income (loss) - - - ( 4,422,513 ) ( 74 ) ( 4,422,587 ) Balance on September 30, 2024 13,870,510 $ 1,387 $ 132,886,700 $ ( 125,979,877 ) $ ( 328,483 ) $ 6,579,727 Balance 13,870,510 $ 1,387 $ 132,886,700 $ ( 125,979,877 ) $ ( 328,483 ) $ 6,579,727 The accompanying notes are an integral part of these consolidated financial statements. 3 Ensysce Biosciences, Inc. Consolidated Statements of Cash Flows (U naudited ) 2024 2023 Nine Months Ended September 30, 2024 2023 Cash flows from operating activities: Net loss $ ( 4,422,587 ) $ ( 7,121,914 ) Adjustments to reconcile net loss to net cash used in operating activities: Accrued interest and interest expense related to note conversions 33,175 9,146 Amortization of original issue discount and debt issuance costs 1,197,200 - Change in fair value of liability classified warrants ( 23,175 ) ( 279,873 ) Change in fair value of convertible notes - ( 146,479 ) Stock-based compensation 80,574 250,224 Lease cost - ( 135 ) Changes in operating assets and liabilities: Unbilled receivable ( 1,685,244 ) 169,083 Prepaid expenses and other assets ( 1,729,252 ) 1,235,252 Accounts payable ( 57,666 ) ( 2,027,375 ) Accrued expenses and other liabilities ( 131,635 ) ( 1,066,036 ) Net cash used in operating activities ( 6,738,610 ) ( 8,978,107 ) Cash flows from financing activities: Proceeds public offerings, net 1,670,001 9,050,004 Proceeds from warrant exercises 2,075,219 - Proceeds from warrant inducement, net of issuance costs 8,103,943 - Transaction costs associated with public offerings - ( 447,879 ) Transaction costs associated with public offering and warrant inducements ( 1,319,115 ) - Repayments of convertible notes ( 485,190 ) ( 1,000,208 ) Repayment of financed insurance premiums ( 276,260 ) ( 307,131 ) Net cash provided by financing activities 9,768,598 7,294,786 Increase (decrease) in cash and cash equivalents 3,029,988 ( 1,683,321 ) Cash and cash equivalents beginning of period 1,123,604 3,147,702 Cash and cash equivalents end of period $ 4,153,592 $ 1,464,381 Supplemental disclosure of non-cash investing and financing activities: Incremental fair value of August 2024 Warrant Inducement $ 10,210,616 $ - Incremental fair value of February 2024 Warrant Inducement $ 5,167,372 $ - Conversions of convertible notes into common stock $ 1,168,600 $ 3,056,892 Proceeds from financed insurance premiums, net $ 232,155 $ 445,737 Transaction costs from warrant inducement and public offering included in accounts payable $ 125,641 $ - Deemed dividend related to warrants down round provision $ 290 $ 12,038 Settlement of commitment fee in shares $ - $ 400,000 The accompanying notes are an integral part of these consolidated financial statements. 4 ENSYSCE BIOSCIENCES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its 79.2 %-owned subsidiary, EBIR, Inc. (“EBIR”, formerly known as Covistat, Inc.) and its wholly-owned subsidiaries EBI Operating, Inc. and EBI OpCo, Inc. (collectively, the “Company”), is a clinical-stage pharmaceutical company using its proprietary technology platforms to develop safer prescription drugs. The primary focus of the Company is developing abuse- and overdose-resistant pain technology, with a lead product candidate in the abuse-resistant, TAAP (Trypsin-Activated Abuse Protection) opioid, PF614. In addition, the Company is developing its MPAR ® (Multi-Pill Abuse Resistance) technology for overdose protection, which is being applied to the PF614 program with a second product candidate, PF614-MPAR. The Company is also applying its TAAP and MPAR ® technology to a methadone prodrug for use in the treatment of Opioid Use Disorder. In 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the certificate of incorporation, EBIR was authorized to issue 1,000,000 shares of common stock, $ 0.001 par value per share, and 100,000 shares of preferred stock, $ 0.001 par value per share. Ensysce is a 79.2 % stockholder in EBIR, with 9.9 % and 10.9 % of the shares held by a certain key person of the Company and two unrelated parties, respectively. The non-Ensysce owned shares and the activity are reflected on the financial statements as Noncontrolling interests. The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer. NOTE 2 - BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the nine months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2023, which may be found in the Company’s Form 10-K filed with the SEC on March 15, 2024. Going concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. 5 While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates and assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services. Cash and cash equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Additionally, the Company had concentration in accounts payable, as one and two research and development vendors, respectively, made up greater than 10% individually, and 72 % and 38 % in aggregate , of the outstanding accounts payable balance as of September 30, 2024, and December 31, 2023, respectively. Property and equipment Property and equipment are fully depreciated and as such there is no depreciation expense recognized in the periods presented. Fair Value Measurement ASC 820, Fair Value Measurements , (“ASC 820”) provides guidance on the development and disclosure of fair value measurements. Pursuant to ASC 820, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of September 30, 2024, and December 31, 2023, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 6 Warrants The Company issued liability-classified warrants in connection with the issuance of the 2021 Notes and the 2022 Notes. The warrants were liability-classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black-Scholes model to estimate the fair value of the warrants by using assumptions within the model for the expected volatility, expected term, risk-free interest rate and dividend yield. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of September 30, 2024, and December 31, 2023. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 September 30, 2024 Total Level 1 Level 2 Level 3 Liability classified warrants $ 3,213 $ - $ - $ 3,213 Total $ 3,213 $ - $ - $ 3,213 Total Level 1 Level 2 Level 3 December 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants 26,388 - - 26,388 Total $ 26,388 $ - $ - $ 26,388 The following table summarizes the change in fair value of the Company’s Level 3 liabilities for the nine months ended September 30, 2024 (no level 3 assets as of the nine months ended September 30, 2024): SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Liability classified warrants Fair value, December 31, 2023 $ 26,388 Change in fair value ( 23,175 ) Fair value, September 30, 2024 $ 3,213 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR ® overdose prevention technology (the “MPAR Grant”). The initial grant was extended several times and cumulative funding under this grant of approximately $ 10.7 million was completed in December 2023. A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing funding of $ 14 million through May 2027. 7 In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”). The total approved budget was approximately $ 5.4 million, and the grant period ended August 31, 2024. The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”), applied by analogy, to ensure that it recognizes revenues to reflect the transfer of promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services, even though there is no “exchange” as defined in ASC 606. The Company believes the recognition of revenue as costs are incurred and reimbursable amounts become due is analogous to the concept of transfer of control of a service over time under ASC 606. The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS 2024 2023 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 MPAR $ 1,782,805 $ 119,942 $ 1,782,805 $ 1,038,484 TAAP/OUD 1,636,048 315,438 2,123,567 677,004 Total $ 3,418,853 $ 435,380 $ 3,906,372 $ 1,715,488 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted in a timely manner, no valuation allowances are recorded. Research and development costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and administrative expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards. 8 Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Net income (loss) per share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic shares outstanding include the weighted average effect of the Company’s outstanding pre-funded warrants and abeyance shares, which require no consideration for the delivery of shares of common stock. Diluted net income (loss) per share is calculated by adjusting basic shares outstanding for the dilutive effect of common share equivalents outstanding for the period. The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2024 2023 2024 2023 Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Stock options 580,414 26,354 580,414 26,354 RSUs - 63 - 63 Warrants 18,830,377 4,711,236 13,194,861 2,876,380 Convertible notes 137,799 - 137,799 - Total 19,548,590 4,737,653 13,913,074 2,902,797 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,” including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements. ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. Adoption of this ASU is currently being evaluated by the Company. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. 9 NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS September 30, 2024 December 31, 2023 Prepaid research and development $ 2,652,845 $ 535,474 Prepaid insurance 378,360 441,871 Other prepaid expenses 104,905 72,358 Other current assets 18,000 18,000 Total prepaid expenses and other current assets $ 3,154,110 $ 1,067,703 NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES September 30, 2024 December 31, 2023 Accrued research and development $ 214,251 $ 329,228 Professional fees 95,730 110,202 Other accrued liabilities 137,054 102,830 Total accrued expenses and other liabilities $ 447,035 $ 542,260 NOTE 6 – COMMITMENTS AND CONTINGENCIES Purchase Commitments As of September 30, 2024, the Company’s commitments included approximately $ 13.3 million related to the Company’s open purchase orders and contractual obligations that occurred in the ordinary course of business, including commitments with contract research organizations for multi-year pre-clinical and clinical research studies. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or the performance of services. Litigation As of September 30, 2024, and December 31, 2023, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. 10 Lease The Company’s current lease agreement (as amended) has a term that extends through October 31, 2025, with no contracted option to renew. As of September 30, 2024, the future lease payments totaled $ 38,294 . The Company recognized total rent expense of $ 8,747 and $ 26,242 in the three and nine months ended September 30, 2024, and $ 8,375 and $ 25,124 in the three and nine months ended September 30, 2023. NOTE 7 – NOTES PAYABLE The following table provides a summary of the Company’s outstanding debt as of September 30, 2024: SCHEDULE OF DEBT Principal balance Accrued interest Net debt balance 2023 Notes $ 216,000 $ 6,308 - $ 222,308 Financed insurance 164,868 - - 164,868 Total $ 380,868 $ 6,308 - $ 387,176 The following table provides a summary of the Company’s outstanding debt as of December 31, 2023: December 31, 2023 Principal balance Accrued interest Unamortized Debt Discount and Issuance Costs Net debt balance 2023 Notes $ 1,836,000 $ 13,078 $ ( 1,197,200 ) $ 651,878 Financed insurance 197,249 5,570 - 202,819 Total $ 2,033,249 $ 18,648 $ ( 1,197,200 ) $ 854,697 11 Interest Expense The interest expense recognized for notes payable was as follows: SCHEDULE OF INTEREST EXPENSE FOR NOTES PAYABLE 2024 2023 2024 2023 Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Stated interest accrual $ 4,063 $ 7,649 $ 6,155 $ 9,146 2023 Notes - - 1,273,536 - Total $ 4,063 $ 7,649 $ 1,279,691 $ 9,146 2023 Notes On October 23, 2023, the Company entered into a Securities Purchase Agreement (“SPA”) for an aggregate financing of $ 1.8 million with investors, including $ 0.2 million with a board member. At the first closing under the SPA, which occurred on October 25, 2023, the Company issued to the investors (i) senior secured convertible promissory notes in the aggregate principal amount of $ 612,000 for an aggregate purchase price of $ 566,667 and (ii) warrants to purchase 1,255,697 shares of the Company’s common stock, par value $ 0.0001 per share in the aggregate. At the second closing under the SPA, which occurred on November 29, 2023, the Company issued to the investors referenced above, (i) additional notes in the aggregate principal amount of $ 1,224,000 for an aggregate purchase price of $ 1,133,333 and (ii) additional warrants to purchase 2,511,394 shares of the common stock in the aggregate. The Company reflected the outstanding principal amount, the remaining unamortized discount (both original issue discount and the relative fair value discount associated with the warrants discussed below) and the remaining debt issuance costs as a net amount on the face of the balance sheet. The amortization of the original debt discount (approximately $ 0.1 million) and issuance costs (approximately $ 0.3 million) were recorded as interest expense within the consolidated statements of operations. As of September 30, 2024, the original debt discount and issuance costs were fully amortized to interest expense. The warrants have an exercise price of $ 1.5675 , the same as the conversion price, and are exercisable for five years following the issuance date. The warrants were equity classified as they are indexed to the Company’s stock and only settleable in shares. The warrants were initially measured at fair value using a Black-Scholes valuation model and were allocated along with the 2023 Notes using the relative fair value method. The initial fair value of $ 1.1 million allocated to the warrants was considered a debt discount and was amortized to interest expense over the remaining term of the notes. As of September 30, 2024, the discount associated with the warrants was fully amortized to interest expense. 12 During 2024, the Company converted 745,521 shares of common stock with a conversion value of $ 1.2 million related to the 2023 Notes. In addition, in connection with the SPA, the Company incurred a $ 1.0 million waiver fee as a result of the 2024 February Warrant Inducement (see Note 8) to pay down $ 0.5 million of the 2023 Notes and incurred $ 0.5 million in transaction costs recorded as such in the consolidated statement of stockholders’ equity. As of September 30, 2024, the remaining amount of the 2023 Notes relates to senior secured convertible promissory notes held by a Company board member (see Note 10). Financed insurance premiums In June 2024, the Company renewed and financed its directors’ and officers’ liability insurance in the amount of $ 0.2 million. Monthly payments are scheduled from July 2024 through March 2025. NOTE 8 - STOCKHOLDERS’ EQUITY The Company’s current Certificate of Incorporation authorizes 250,000,000 shares of common stock and 1,500,000 shares of preferred stock, both with par value equal to $ 0.0001 . As of September 30, 2024, and December 31, 2023, there were no shares of preferred stock issued and outstanding. 2024 February Warrant Inducement In February 2024, the Company executed an Inducement Letter with certain holders of existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock issued to the holders in connection with the 2023 May Offering. Pursuant to the Inducement Letter, the holders agreed to exercise for cash their existing warrants to purchase an aggregate of 3,601,752 shares of Common Stock at a reduced exercise price of $ 1.31 per share in consideration of the Company’s agreement to issue new unregistered Series A Warrants (the “Series A Warrants”) to purchase up to 3,601,752 shares of Common Stock and new unregistered Series B Warrants (the “Series B Warrants”) to purchase up to 3,601,752 shares of Common Stock (collectively, the “New Warrant Shares”). The Series A Warrants have an exercise price of $ 1.06 per share and have a term equal to eighteen months from the date of issuance. The Series B Warrants have an exercise price of $ 1.06 per share and will expire on May 12, 2028 . The gross proceeds to the Company from the exercise of the warrants were approximately $ 4.7 million, prior to deducting placement agent fees and estimated offering expenses. As the existing warrants and the new warrants were equity classified before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $ 5.2 million as an equity issuance cost. In connection with the execution of the Inducement Letter, the Company executed a waiver related to the 2023 Notes’ SPA it had entered as of October 23, 2023. The SPA contained restrictions on the Company’s ability to undertake certain transactions, which included the execution of the Inducement Letter. The Waiver permitted the Company to execute the Inducement Letter but required repayment of the certain investor held notes issued under the SPA with a premium following closing of the transaction. Refer to Note 7 for the details of the waiver fee and the application of the amounts to the outstanding 2023 Notes and as a transaction cost of the warrant inducement. The Company utilized an exclusive placement agent for the 2024 February Warrant Inducement and incurred approximately $ 0.3 million in legal fees and other closing costs. Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 252,123 shares of Common Stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction . The placement agent warrants expire on May 12, 2028 , and have an exercise price of $ 1.6375 per share of Common Stock (equal to 125% of the reduced exercise price per Existing Warrant). 2024 Registered Direct Offering and 2024 August Warrant Inducement In August 2024, the Company entered into a definitive Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell in a registered direct offering, (i) an aggregate of 2,490,798 shares of common stock, par value $ 0.0001 per share at an offering price of $ 0.47 per share, (ii) pre-funded warrants to purchase up to 1,062,396 shares of common stock, at a price per pre-funded warrant equal to $ 0.4699 , the price per share less $ 0.0001 , for gross proceeds of approximately $ 1.67 million before the deduction of placement agent fees and offering expenses. The pre-funded warrants were subsequently exercised in full and were not outstanding as of September 30, 2024. The Company also entered into the August Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants to purchase up to an aggregate of 7,203,504 shares of common stock of the Company originally issued in February 2024, having an exercise price of $ 1.06 per share, at a reduced exercise price of $ 0.47 per share. The Company also agreed to amend certain existing warrants to purchase up to an aggregate of 2,000,000 shares of common stock that were previously issued in November 2023 and have an exercise price of $ 1.5675 per share such that the amended warrants will have a reduced exercise price of $ 0.47 per share effective upon the closing of the offering and will be exercisable from the date on which stockholder approval is received with respect to the issuance of the shares of common stock issuable upon exercise of such warrants. As the existing November 2023 and February 2024 warrants and their related newly issued warrants upon inducement were equity classified before and after the exchange, and as the exchange is directly attributable to an equity offering, the Company recognized the effect of the modification of approximately $ 10.2 million as an equity issuance cost. In a concurrent private placement, pursuant to the terms of the August Inducement Letter and Securities Purchase Agreement, the Company utilized an exclusive placement agent for the 2024 Registered Direct Offering and 2024 August Warrant Inducement and incurred approximately $ 0.6 million in legal fees and other closing costs. Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 752,969 shares of Common Stock . The placement agent warrants expire on August 28, 2029 , and have an exercise price of $ 0.5875 per share of Common Stock. The warrants will become exercisable upon stockholder approval and contain customary anti-dilution adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions. 13 Abeyance Shares Related to the 2024 February Warrant Inducement, a holder left 1,488,144 shares in abeyance at the Company’s transfer agent to be delivered to the holder at their request. During the quarter ended September 30, 2024, all remaining shares held in abeyance were delivered to the holder. Related to the 2024 August Warrant Inducement, four holders left 7,203,504 shares in abeyance at the Company’s transfer agent to be delivered to the holder at their request. During the quarter ended September 30, 2024, 1,500,000 shares held in abeyance were delivered to the holders. Accordingly, as of September 30, 2024, 5,703,504 shares were held in abeyance, had not been issued and were not outstanding. Subsequent to September 30, 2024, the remaining shares were delivered to the holders. Warrants The following table provides a summary of outstanding warrants to purchase shares of common stock as of September 30, 2024: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 29,469,869 $ 0.47 - $ 0.5875 August 2024 Warrants Equity (b) 252,123 $ 1.64 February 2024 Warrants Equity (c) 2,443,187 $ 0.47 - $ 1.5675 2023 Notes Warrants Equity (d) 1,101,582 $ 3.64 - $ 2,760 Other Warrants Equity & Liability 33,266,761 (a) On August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement , the Company issued equity classified warrants to purchase 29,469,869 shares to certain institutional investors and the placement agent. The warrants were issued in connection with the 2024 Registered Direct Offering and the 2024 August Warrant Inducement. The 28,716,900 investor warrants have an exercise price of $ 0.47 per share, and are exercisable from the date on which stockholder approval is received. One half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they are exercisable. The 752,969 placement agent warrants have an exercise price of $ 0.5875 per share, are exercisable upon stockholder approval and expire August 28, 2029. (b) On February 12, 2024, the Company issued 7,455,627 equity classified warrants (Series A Warrants, Series B Warrants and placement agent warrants) in connection with the Inducement Letter for the 2024 February warrant inducement and related warrant restructuring. The Series A and Series B Warrants were immediately exercisable with an exercise price of $ 1.06 per share and expire on August 14, 2025 and May 12, 2028 , respectively. The placement agent warrants were immediately exercisable with an exercise price of $ 1.6375 per share and expire on May 12, 2028 . In connection with the 2024 August Warrant Inducement, 7,203,504 warrants were exercised. As of September 30, 2024, the placement agents remain outstanding. (c) On October 25, 2023, and November 28, 2023, the Company issued warrants to purchase 1,255,697 shares and 2,511,394 shares, respectively. The warrants were immediately exercisable with an exercise price of $ 1.5675 per share and expire on October 25, 2028 , and November 28, 2028 , respectively. In January 2024, a holder of the warrants exercised 1,323,904 warrants at an exercise price of $ 1.5675 per share. In August 2024, an inducement letter was issued to a holder of 2,000,000 warrants to reduce the exercise price from $ 1.5675 to $ 0.47 per share, subject to the receipt of stockholder approval. (d) At various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of 1,101,582 warrants to provide holders the right to purchase common stock at exercise prices ranging from $ 3.64 - $ 2,760 per share. A total of 41,666 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW. A total of 43,418 outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash settlement features embedded within the warrant agreements. The remaining warrants are equity classified. The warrants expire beginning June 30, 2026 , through August 7, 2028 . 14 NOTE 9 - STOCK-BASED COMPENSATION In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan. In February 2024, the Company’s Board approved an annual increase of 157,304 shares available for future grant under the 2021 Omnibus Plan. The Company recognized stock-based compensation expense within general and administrative expense of $ 14,497 and $ 56,643 for the three and nine months ended September 30, 2024, and $ 41,336 and $ 198,000 for the three and nine months ended September 30, 2023. The Company recognized stock-based compensation expense within research and development expense of $ 6,322 and $ 23,931 for the three and nine months ended September 30, 2024, and $ 14,338 and $ 52,224 for the three and nine months ended September 30, 2023. Option Activity There were no stock options granted during the nine months ended September 30, 2024. The following table summarizes the Company’s stock option activity during the nine months ended September 30, 2024: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2023 581,314 $ 33.15 9.57 $ - Granted - - - - Exercised - - - - Expired / Forfeited - - - - Outstanding at September 30, 2024 581,314 33.15 8.83 - Exercisable at September 30, 2024 580,414 32.48 - - Vested and expected to vest 581,314 33.15 8.83 - 15 Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in during the nine months ended September 30, 2024 and 2023): ● Expected stock-price volatility. The expected volatility is derived from the historical volatilities of publicly traded companies within the Company’s industry that the Company considers to be comparable to the Company’s business over a period approximately equal to the expected term. ● Expected term. The expected term represents the period that the stock-based awards are expected to be outstanding. The Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term due to a lack of sufficient data. Therefore, the Company estimates the expected term for employees by using the simplified method provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. ● Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term. ● Expected dividend yield. The expected dividend is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on the Company’s common stock. As of September 30, 2024, the Company had an aggregate of $ 39,273 of unrecognized share-based compensation cost, which is expected to be recognized over the weighted average period of 0.83 years. Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE September 30, 2024 Awards outstanding under the 2021 Omnibus Incentive Plan 581,314 Awards available for future grant under 2021 Omnibus Incentive Plan 159,416 Warrants outstanding 33,266,761 Total shares of common stock reserved for future issuance 34,007,491 NOTE 10 - RELATED PARTIES As of September 30, 2024, the Company held a $ 0.2 million senior secured convertible promissory note plus accrued interest and 0.4 million warrants exercisable for common stock at $ 1.5675 per share issued to a board member in connection to the issuance of the 2023 Notes. On April 25, 2024, the Company and the board member entered into a forbearance agreement that will expire on April 25, 2025 . Upon termination of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest. The Company may pay the notes in full at any time prior to the conclusion of the forbearance period. 16